Asset Details
Do you wish to reserve the book?
NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm
Do you wish to request the book?
NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm
2012
Overview
The current World Health Organization (WHO) classification includes two types of natural killer (NK)-cell lymphomas: extranodal NK/T-cell lymphoma, nasal type (ENKL), and aggressive NK-cell leukemia (ANKL). These diseases are mostly endemic to East Asia and Latin America. The Epstein–Barr virus (EBV) is usually detected in tumor cells, suggesting that EBV plays an important role in lymphomagenesis. At the site of origin, ENKL can be divided into two major subtypes: nasal and extranasal diseases. The advanced disease presentation, highly aggressive clinical course, and poor prognosis of the latter are analogous to ANKL. It is well known that P-glycoprotein, which is a product of the multi-drug resistance (
MDR1
) gene, is expressed on neoplastic cells of ENKL or ANKL. This is a major cause of the refractoriness of malignant lymphoma to conventional chemotherapeutic regimens containing anthracycline. Recent studies, however, have identified that L-asparaginase-containing regimens, such as SMILE (steroid, methotrexate, ifosfamide, L-asparaginase and etoposide), are effective for ENKL. Considering the myelotoxicity of SMILE, its use in the treatment of ANKL needs some modifications, but this treatment scheme is promising in improving the prognosis of NK-cell lymphomas.
Publisher
Current Science Inc
Subject
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Humans
/ Killer Cells, Natural - pathology
/ Leukemia, T-Cell - drug therapy
/ Leukemia, T-Cell - pathology
/ Lymphoma, T-Cell - drug therapy
/ Lymphoma, T-Cell - pathology
/ Medicine
/ Methotrexate - therapeutic use
/ Nose Neoplasms - complications
/ Oncology
